A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT ID: NCT01798485

Last Updated: 2016-07-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

696 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preliminary signals of clinical activity of ganetespib as a single agent have been observed in patients with advanced NSCLC. A Phase 2b/3 Study (9090-08) was initiated to evaluate the safety and activity of ganetespib in combination with docetaxel vs. docetaxel alone in NSCLC. Study 9090-08 is ongoing. Results from an interim analysis show that the combination has been well tolerated and an encouraging improvement in efficacy, including overall survival (OS) has been observed.

Update: An independent data monitoring committee (DMC) was established to review accumulating unblinded safety data, and efficacy data at two specified Interim Analyses. The DMC monitored the conduct of the trial (including the accrual/retention of patients) and reviewed the risks and benefits. The study was stopped after the first Interim Analysis due to futility.

The efficacy portion of this report is based on a 05 October 2015 data cut after the number of protocol-defined death events (336) for the first interim analysis had been achieved. The safety portion is based on the final database locked on 23 December 2015.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small-Cell Lung Adenocarcinoma Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ganetespib and Docetaxel

Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.

Group Type EXPERIMENTAL

Docetaxel

Intervention Type DRUG

Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.

Ganetespib

Intervention Type DRUG

Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.

Docetaxel

Docetaxel (75 mg/m\^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.

Group Type ACTIVE_COMPARATOR

Docetaxel

Intervention Type DRUG

Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docetaxel

Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.

Intervention Type DRUG

Ganetespib

Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Taxotere Docecad STA-9090

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
* Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1
* Prior therapy defined as 1 prior systemic therapy for advanced disease
* Documented disease progression during or following most first line therapy for advanced disease
* Adequate hematologic, hepatic, renal function

Exclusion Criteria

* Epidermal growth factor receptor (EGFR) mutations
* Anaplastic lymphoma kinase (ALK) translocations
* Predominantly squamous, adenosquamous or unclear histologic type
* Active or untreated central nervous system (CNS) metastases
* Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
* Serious cardiac illness or medical conditions
* Pregnant or lactating women
* Uncontrolled intercurrent illness
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Synta Pharmaceuticals Corp.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Oncology Associates PC- NAHOA

Flagstaff, Arizona, United States

Site Status

Arizona Oncology Associates, PC- NAHOA

Prescott Valley, Arizona, United States

Site Status

Northern Arizona Hematology & Oncology Associates

Sedona, Arizona, United States

Site Status

Arizona Clinical Research Center, Inc.

Tucson, Arizona, United States

Site Status

Pacific Cancer Medical Center, Inc

Anaheim, California, United States

Site Status

Comprehensive Blood & Cancer Center

Bakersfield, California, United States

Site Status

City of Hope Comprehensive Breast Cancer Center

Duarte, California, United States

Site Status

UC San Diego Moores Cancer Center

La Jolla, California, United States

Site Status

Loma Linda University Cancer Center

Loma Linda, California, United States

Site Status

VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

St. Joseph Hospital, Center for Cancer Prevention and Treatment

Orange, California, United States

Site Status

Cancer Care Associates Medical Group, Inc.

Redondo Beach, California, United States

Site Status

UC Davis Medical Center - UC Davis Comprehensive Cancer

Sacramento, California, United States

Site Status

Santa Barbara Hematology Oncology Medical Group, Inc.

Santa Barbara, California, United States

Site Status

City of Hope- South Pasadena

South Pasadena, California, United States

Site Status

Rocky Mountain Cancer Center

Denver, Colorado, United States

Site Status

Eastern Connecticut Hematology Associates

Norwich, Connecticut, United States

Site Status

Medical Oncology Hematology Consultants, PA

Newark, Delaware, United States

Site Status

Lynn Cancer Institute Center for Hematology Oncology

Boca Raton, Florida, United States

Site Status

Halifax Health - Medical Center

Daytona Beach, Florida, United States

Site Status

University of Miami Health System Sylvester at Deerfield Beach

Deerfield Beach, Florida, United States

Site Status

Memorial Regional Hospital

Hollywood, Florida, United States

Site Status

Baptist Health Medical Group Oncology, LLC

Miami, Florida, United States

Site Status

University of South Florida - H. Lee Moffitt

Tampa, Florida, United States

Site Status

Palm Beach Cancer Institute

West Palm Beach, Florida, United States

Site Status

Emory University - Winship Cancer Institute

Atlanta, Georgia, United States

Site Status

Northwest Georgia Oncology Centers, PC

Marietta, Georgia, United States

Site Status

University Of Chicago Medical Center

Chicago, Illinois, United States

Site Status

Cancer Care Specialists of Central Illinois, S.C.

Decatur, Illinois, United States

Site Status

Saint Anthony Medical Center

Rockford, Illinois, United States

Site Status

Fort Wayne Medical Oncology and Hematology Inc

Fort Wayne, Indiana, United States

Site Status

AAMC Oncology and Hematology

Annapolis, Maryland, United States

Site Status

The Center for Cancer and Blood Disorders (CCBD) - Bethesda

Bethesda, Maryland, United States

Site Status

The John R Marsh Cancer Center

Hagerstown, Maryland, United States

Site Status

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Sparrow Regional Cancer Center

Lansing, Michigan, United States

Site Status

St. Luke's Hospital Duluth

Duluth, Minnesota, United States

Site Status

Frauenshuh Cancer Center

Saint Louis Park, Minnesota, United States

Site Status

St. Louis Cancer Care, LLP - North County

Bridgeton, Missouri, United States

Site Status

Renown Regional Medical Center

Reno, Nevada, United States

Site Status

Hackensack University Medical Center - John Theurer Cancer Center

Hackensack, New Jersey, United States

Site Status

New Mexico Cancer Center

Albuquerque, New Mexico, United States

Site Status

North Shore Hematology Oncology Associates

East Setauket, New York, United States

Site Status

Clinical Research Alliance

Lake Success, New York, United States

Site Status

University Of North Carolina At Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Novant Health Presbyterian Medical Center

Charlotte, North Carolina, United States

Site Status

New Hanover Regional Medical Center - Zimmer Cancer Center

Wilmington, North Carolina, United States

Site Status

Novant Health Oncology Specialists

Winston-Salem, North Carolina, United States

Site Status

Tulsa Cancer Institute, PLLC

Tulsa, Oklahoma, United States

Site Status

Kaiser Permanente Northwest

Portland, Oregon, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Guthrie Medical Group, PC

Sayre, Pennsylvania, United States

Site Status

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Site Status

Prairie Lakes Healthcare System

Watertown, South Dakota, United States

Site Status

Erlanger Institute for Clinical Research

Chattanooga, Tennessee, United States

Site Status

Associates In Oncology and Hematology

Chattanooga, Tennessee, United States

Site Status

Thompson Cancer Survival Center

Knoxville, Tennessee, United States

Site Status

Texas Oncology-Arlington North

Arlington, Texas, United States

Site Status

Texas Oncology - Arlington South

Arlington, Texas, United States

Site Status

Texas Oncology, P.A.

Beaumont, Texas, United States

Site Status

Texas Oncology, PA

Dallas, Texas, United States

Site Status

Simmons Comprehensive Cancer Center

Dallas, Texas, United States

Site Status

Houston Methodist Hospital Research Institute

Houston, Texas, United States

Site Status

Millennium Oncology

Houston, Texas, United States

Site Status

Joe Arrington Cancer Research and Treatment Center

Lubbock, Texas, United States

Site Status

Cancer Care Centers Of South Texas

San Antonio, Texas, United States

Site Status

Cancer Care Centers Of South Texas

San Antonio, Texas, United States

Site Status

Cancer Care Centers of South Texas

San Antonio, Texas, United States

Site Status

Texas Oncology - Sherman

Sherman, Texas, United States

Site Status

Providence Regional Medical Center Everett

Everett, Washington, United States

Site Status

Cancer Care Northwest

Spokane Valley, Washington, United States

Site Status

Northwest Medical Specialties, PLLC

Tacoma, Washington, United States

Site Status

Mary Babb Cancer Center

Morgantown, West Virginia, United States

Site Status

Green Bay Oncology, Ltd. - St. Mary's Site

Green Bay, Wisconsin, United States

Site Status

Green Bay Oncology

Green Bay, Wisconsin, United States

Site Status

Landesklinikum Krems

Krems, Lower Austria, Austria

Site Status

Bezirkskrankenhaus Kufstein [Onkologie]

Kufstein, Tyrol, Austria

Site Status

Krankenhaus Der Barmherzigen Schwestern

Linz, Upper Austria, Austria

Site Status

Klinikum Wels-Grieskirchen

Wels, Upper Austria, Austria

Site Status

Allgemeines Krankenhaus Linz

Linz, , Austria

Site Status

Elisabeth Linz Hospital

Linz, , Austria

Site Status

Otto Wagner Spital

Vienna, , Austria

Site Status

Sozialmedizinisches Zentrum Baumgartner Höhe

Vienna, , Austria

Site Status

AZ Sint-Maarten - Campus Leopoldstraat

Mechelen, Antwerpen, Belgium

Site Status

Clinique Saint-Pierre Ottignies

Ottignies, Brabant Wallon, Belgium

Site Status

Grand Hôpital de Charleroi - Site Notre-Dame

Charleroi, Hainaut, Belgium

Site Status

INDC Entité Jolimontoise - Polyclinique de Jolimont

Haine-Saint-Paul, Hainaut, Belgium

Site Status

CHU Dinant Godinne UCL Namur

Yvoir, Namur, Belgium

Site Status

Algemeen Stedelijk Ziekenhuis - Campus Aalst

Roeselaere, West-Vlaanderen, Belgium

Site Status

Cliniques Universitaire Saint-Luc

Brussels, , Belgium

Site Status

CHR de la Citadelle - Site Citadelle

Liège, , Belgium

Site Status

Clinical Centre Banja Luka

Banja Luka, Republika Srpska, Bosnia and Herzegovina

Site Status

University Clinical Center Tuzla

Tuzla, Tuzlanski kanton, Bosnia and Herzegovina

Site Status

Clinical Hospital Mostar

Mostar, , Bosnia and Herzegovina

Site Status

Clinical Center University of Sarajevo, Clinic of Oncology

Sarajevo, , Bosnia and Herzegovina

Site Status

University Clinical Centre Sarajevo

Sarajevo, , Bosnia and Herzegovina

Site Status

University Clinical Center Tuzla

Tuzla, , Bosnia and Herzegovina

Site Status

Kantonalna bolnica Zenica

Zenica, , Bosnia and Herzegovina

Site Status

Princess Margaret Hospital

Toronto, Ontario, Canada

Site Status

Mc Gill University-MUHC

Montreal, Quebec, Canada

Site Status

University Hospital Center Zagreb

Zagreb, City of Zagreb, Croatia

Site Status

Opca bolnica Pula

Pula, Istria County, Croatia

Site Status

Fakultni nemocnice Olomouc

Olomouc, , Czechia

Site Status

Fakultni nemocnice Ostrava

Ostrava - Poruba, , Czechia

Site Status

Vseobecna fakultni nemocnice v Praze

Prague, , Czechia

Site Status

Nemocnice Na Bulovce

Prague, , Czechia

Site Status

CHI des Alpes du Sud

Gap, Hautes-Alpes, France

Site Status

Centre D'Oncologie Du Pays Basque

Bayonne, Pyrénées-Atlantiques, France

Site Status

Centre Hosptalier De Villefranche-Sur-Saone

Villefranche-sur-Saône, Rhône, France

Site Status

Chi creteil

Créteil, Val-de-Marne, France

Site Status

Chu De Grenoble - Hopital Michallon

Grenoble, , France

Site Status

Centre Léon Bérard

Lyon, , France

Site Status

Groupe Hospitalier Cochin

Paris, , France

Site Status

Centre Hospitalier Universitaire de Rennes - Hopital d

Rennes, , France

Site Status

Hôpital Charles Nicolle

Rouen, , France

Site Status

CHRU de Strasbourg

Strasbourg, , France

Site Status

Universitätsklinikum Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

Universiaetsklinikum Ulm

Ulm, Baden-Wurttemberg, Germany

Site Status

Schwarzwald-Baar-Klinikum

Villingen-Schwenningen, Baden-Wurttemberg, Germany

Site Status

Asklepios Fachklinik München-Gauting

Gauting, Bavaria, Germany

Site Status

Klinikum Bogenhausen

Munich, Bavaria, Germany

Site Status

Gesundheitszentrum Wetterau

Bad Nauheim, Hesse, Germany

Site Status

Johann Wolfgang Goethe University Clinic Frankfurt

Frankfurt am Main, Hesse, Germany

Site Status

Johann Wolfgang Goethe University Clinic Frankfurt

Frankfurt am Main, Hesse, Germany

Site Status

Klinikum Kassel

Kassel, Hesse, Germany

Site Status

Kliniken der Stadt Köln gGmbH

Cologne, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum des Saarlandes

Homburg, Saarland, Germany

Site Status

Universitätsklinikum Leipzig [Pneumologie]

Leipzig, Saxony, Germany

Site Status

Pneumologisches Forschungsinstitut an der Lungenclinic Gross

Großhansdorf, Schleswig-Holstein, Germany

Site Status

MVZ Äerzteforum Seestraße

Berlin, , Germany

Site Status

Ev. Krankenhaus Bielefeld

Bielefeld, , Germany

Site Status

Klinikum Frankfurt An Der Oder

Frankfurt (Oder), , Germany

Site Status

Practice Laack

Hamburg, , Germany

Site Status

Unikl. Schleswig-Holstein - Lübeck

Lübeck, , Germany

Site Status

J. Gutenberg Uni.Mainz

Mainz, , Germany

Site Status

Medizinische Fakultät Mannheim Uni Heidelberg

Mannheim, , Germany

Site Status

Gemeinschaftspraxis fuer Haematologie und Onkologie

Münster, , Germany

Site Status

Klinikum Offenbach GmbH

Offenbach, , Germany

Site Status

Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó

Deszk, Csongrád megye, Hungary

Site Status

Fejér Megyei Szent György Egyetemi Oktató Kórház

Székesfehérvár, Fejér, Hungary

Site Status

Országos Korányi TBC és Pulmonológiai Intézet

Budapest, Pest County, Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Országos Korányi TBC és Pulmonológiai Intézet

Budapest, , Hungary

Site Status

Békés Megyei Pándy Kálmán Kórház

Gyula, , Hungary

Site Status

CRU Hungary Kft.

Miskolc, , Hungary

Site Status

Irccs Irst

Meldola, Forli, Italy

Site Status

Presidio Ospedaliero Centrale Belcolle, AUSL Viterbo

Viterbo, Lazio, Italy

Site Status

Azienda Ospedaliera San Gerardo

Monza, Lombardy, Italy

Site Status

CRO, IRCCS, Istituto Nazionale Tumori

Aviano, Pordenone, Italy

Site Status

Istituti Fisioterapici Ospitalieri Regina Elena

Roma, Roma, Italy

Site Status

Azienda Policlinico Umberto I

Rome, Roma, Italy

Site Status

Policlinico S.Orsola Malpighi, AOU di Bologna

Bologna, , Italy

Site Status

AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can

Genova, , Italy

Site Status

Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a

Milan, , Italy

Site Status

Iov-Irccs

Padua, , Italy

Site Status

Ospedale S.Maria della Misericordia, AO di Perugia, Universi

Perugia, , Italy

Site Status

Ospedale Guglielmo da Saliceto, AUSL Piacenza

Piacenza, , Italy

Site Status

Borgo Roma, Policlinico G.Rossi, AOU Integrata Verona

Verona, , Italy

Site Status

Ziekenhuis Assen

Assen, Drenthe, Netherlands

Site Status

Ziekenhuis St Jansdal

Harderwijk, Gelderland, Netherlands

Site Status

Gelre Ziekenhuis Zutphen

Zutphen, Gelderland, Netherlands

Site Status

academisch ziekenhuis Maastricht

Maastricht, Limburg, Netherlands

Site Status

Isala Klinieken Zwolle

Zwolle, Overijssel, Netherlands

Site Status

Sint Antoniusziekenhuis, location Utrecht

Utrecht, , Netherlands

Site Status

NZOZ Med Polonia

Poznan, Greater Poland Voivodeship, Poland

Site Status

Wielkopolskie Centrum Pulmonologii i Torakochirurgii

Poznan, Greater Poland Voivodeship, Poland

Site Status

Medica Pro Familia Sp. z o.o. S.K.A.

Krakow, Lesser Poland Voivodeship, Poland

Site Status

Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy

Otwock, Masovian Voivodeship, Poland

Site Status

Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie

Warsaw, Masovian Voivodeship, Poland

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego

Łomża, Podlaskie Voivodeship, Poland

Site Status

Szpital Wojewodzki Zespolony

Elblag, Warmian-Masurian Voivodeship, Poland

Site Status

Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

Olsztyn, , Poland

Site Status

Szpital Chorob Pluc im. Sw. Jozefa w Pilchowicach

Pilchowice, , Poland

Site Status

Szpital Specjalistyczny

Prabuty, , Poland

Site Status

Wojewodzki Szpital Specjalistyczny im. M.Kopernika

Lodz, Łódź Voivodeship, Poland

Site Status

Institutul Oncologic "Prof. Dr. Alex. Trestioreanu"

Bucharest, , Romania

Site Status

Spitalul Clinic Coltea

Bucharest, , Romania

Site Status

Spitalul Universitar de Urgenta Bucuresti

Bucharest, , Romania

Site Status

Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca

Cluj-Napoca, , Romania

Site Status

Medisprof

Cluj-Napoca, , Romania

Site Status

Centrul de Oncologie Sf. Nectarie

Craiova, , Romania

Site Status

Institutul Regional de Oncologie Iasi

Iași, , Romania

Site Status

Oncomed

Timișoara, , Romania

Site Status

Synta Pharmaceuticals Investigational Site

Chelyabinsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Ivanovo, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Izhevsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Kemerovo, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Krasnoyarsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Kursk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Lipetsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Moscow, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Nizhny Novgorod, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Novosibirsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Omsk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Oryol, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Rostov-on-Don, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Saint Petersburg, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Saint Petersburg, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Saint Petersburg, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Samara, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Saransk, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Sochi, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Stavropol, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Ufa, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Ufa, , Russia

Site Status

Synta Pharmaceuticals Investigational Site

Yekaterinburg, , Russia

Site Status

Clinical Centre of Serbia

Belgrade, Belgrade, Serbia

Site Status

Clinical Centre Nis

Niš, Nišavski okrug, Serbia

Site Status

Institute for Oncology and Radiology of Serbia

Belgrade, , Serbia

Site Status

Institute for pulmonary diseases of Vojvodine

Kamenitz, , Serbia

Site Status

Clinical Center Kragujevac

Kragujevac, Šumadijski okrug, Serbia

Site Status

Univerzitetna klinika za pljucne bolesti in alergijo Golnik

Golnik, , Slovenia

Site Status

Onkoloski institut Ljubljana

Ljubljana, , Slovenia

Site Status

Xerencia de Xestión Integrada A Coruña Hospital Teresa Herrera

A Coruña, A Coruña, Spain

Site Status

Synta Pharmaceuticals Investigational Site

Málaga, Andalusia, Spain

Site Status

H. Son Llàtzer

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital de Mataró, Consorci Sanitari del Maresme

Mataró, Barcelona, Spain

Site Status

Synta Pharmaceuticals Investigational Site

Santander, Cantabria, Spain

Site Status

Onkologikoa

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Synta Pharmaceuticals Investigational Site

Oviedo, Principality of Asturias, Spain

Site Status

Hospital Universitari Germans Trias i Pujol

Badalona, , Spain

Site Status

H.U. Vall d'Hebrón

Barcelona, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Barcelona, , Spain

Site Status

H.U. Reina Sofía

Córdoba, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Girona, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Madrid, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Madrid, , Spain

Site Status

F. Jiménez Diaz

Madrid, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Madrid, , Spain

Site Status

Hospital Madrid Norte Sanchinarro

Madrid, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocío

Seville, , Spain

Site Status

Hospital Universitari i Politecnic La Fe

Valencia, , Spain

Site Status

Synta Pharmaceuticals Investigational Site

Cherkasy, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Chernivtsi, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Dnipro, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Donetsk, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Donetsk, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Ivano-Frankivsk, , Ukraine

Site Status

Synta Pharmaceuticals Investigative Site

Kharkiv, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Khmelnytskyi, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Kirovohrad, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Kryvyi Rih, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Kyiv, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Makiivka, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Poltava, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Simferopol, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Sumy, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Uzhhorod, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Vinnytsia, , Ukraine

Site Status

Synta Pharmaceuticals Investigational Site

Truro, Cornwall, United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Shrewsbury, Shropshire, United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Sutton, Surrey, United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Swindon, Wiltshire, United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Cardiff, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Edinburgh, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Leicester, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

London, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

London, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

London, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Nottingham, , United Kingdom

Site Status

Synta Pharmaceuticals Investigational Site

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Bosnia and Herzegovina Canada Croatia Czechia France Germany Hungary Italy Netherlands Poland Romania Russia Serbia Slovenia Spain Ukraine United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-004349-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

9090-14

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.